APVO

Aptevo Therapeutics' stock price has been impacted by several events over the past six months. Positive interim results from the Phase 1b/2 clinical trial of mipletamig for AML and MDS have been reported. Executive leadership transitions were announced to support the company's next phase of growth. The company provided its 2025 financial results and business updates. The company's stock slumped after a one-for-eighteen reverse stock split was approved. Aptevo's stock rallied on a $2.1 million registered direct offering and warrant sale. Aptevo Therapeutics has been upgraded to a Zacks Rank #2 (Buy). The share price as of May 5, 2026, was $5.35, representing a decline of 31.32% over the past year.